As pharmaceutical companies introduce new therapies to the U.S. market, they respond to risk-sharing agreements (RSAs) from healthcare providers, which ...

Developing data strategies for the storage, analysis and protection of patient-specific data has never been more critical to the future ...

Many nations have enacted serialization regulations to combat counterfeit products and diversions of legitimate pharmaceutical products, and those that have not are planning ...

The global regulatory landscape is continuously evolving to protect patients and ensure supply chain visibility. Companies will need flexible implementation plans and increasingly agile ...

To explore our 2015 Life Sciences Trends Report, download the PDF here or view an abbreviated overview below. In 2015, ...

Over the last two years, Clarkston Consulting has released its study on Quality in Generic Pharmaceuticals. As in the past, ...

As populations in emerging markets grow and their economies improve, so will the demand for quality, affordable health care. In ...

An article published this month in New York Magazine highlights the recent advancements to the regenerative medicine and medical device ...

Although appearing dead for now, the $106 billion associated with Pfizer’s proposed buyout of AstraZeneca makes it hard to ignore ...

In 2013, US Customs & Border Protection seized more than 2,350 parcels containing counterfeit medical devices and pharmaceutical products valued ...

Together, industry regulations and healthcare reform are impacting how pharmaceutical companies do business. Drug makers are experiencing a heavy financial ...

The hype around 3D printing rose spectacularly in 2013, and with continued progress, it has the potential to revolutionize the ...